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Abstract
Purpose Farmed fish are increasingly raised on feeds containing vegetable oils, which affects their composition and possibly 
health properties. We investigated the effects of consuming farmed salmon, raised on different feeding regimes, on nutrient 
status and health outcomes in healthy subjects.
Methods Salmon were grown on feeds containing mainly fish oil (FO) or rapeseed oil (RO), resulting in an eicosapentaenoic 
acid (EPA) + docosahexaenoic acid (DHA) content of fillets of 2.1 or 0.9 g/100 g, respectively. In a randomized parallel 
controlled trial, 51 healthy subjects were allocated to consume 2 portions/week of FO salmon (n = 17), RO salmon (n = 17) 
or no additional salmon (Control, n = 17) as part of their habitual diet, for 18 weeks. We collected blood at 0, 9 and 18 
weeks to measure omega-3 index (O3I) in red blood cells, plasma markers of cardiovascular risk, serum 25(OH)-vitamin 
 D3 (25(OH)D3) and plasma trace elements.
Results After 18 weeks, O3I was similarly increased in subjects consuming 2 portions/week of FO or RO salmon compared 
to control (both p < 0.05). Serum 25(OH)D3 was significantly higher, whereas plasma triacylglycerols were significantly 
lower in subjects consuming RO salmon compared to control (both p < 0.05). Heart rate was significantly lower in subjects 
consuming FO salmon after 9 weeks, compared to control (p < 0.01). Salmon consumption did not affect other markers.
Conclusion Consuming two portions/week of salmon raised on rapeseed oil rather than fish oil increased the O3I and vitamin 
D status, and decreased plasma triacylglycerols. These outcomes endorse opportunities for developing more sustainable 
feeds within aquaculture food systems.
Clinical trial registry This trial was registered at clinicaltrials.gov as NCT01916434.
Keywords Farmed fish · Fish feeds · Cardiovascular health · Omega-3 index · Vitamin D · Micronutrients
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Introduction
Worldwide, fish is a valuable dietary source of not only 
energy, protein and n-3 long-chain polyunsaturated fatty 
acids (n-3 LCPUFA), but also vitamins such as A and D, 
and micronutrients such as selenium, zinc and magne-
sium [1]. Whilst the health benefits of seafood consump-
tion have traditionally been attributed to its content of n-3 
LCPUFA [1], a recent systematic assessment of the effects 
of n-3 LCPUFA supplements concluded that increasing 
their consumption had little or no effect on mortality or 
cardiovascular health [2]. Nevertheless, two meta-analyses 
of fish intervention studies confirmed that, compared with 
very low fish intake (i.e., < 1 serving/month), low or mod-
erate fish intake (i.e., 1 or 2 servings/week) significantly 
reduced the risk for coronary heart disease and stroke 
[3, 4]. Furthermore, meta-analysis of observational data 
indicated a moderate and inverse association between fish 
consumption and cerebrovascular risk, whilst this was not 
the case for n-3 LCPUFA status in observational studies, 
or supplement intake in primary and secondary preven-
tion trials [5]. This suggests that the beneficial effect of 
fish intake on disease risk could be mediated through an 
interplay of different nutrients in fish.
The total supply of fish for food consumption has 
increased significantly in the past five decades due to 
population growth, rising incomes, urbanization and a 
strong expansion of global production and distribution 
networks. Further growth in fish consumption levels will 
be increasingly dependent on aquaculture. Indeed, aqua-
culture already makes a crucial contribution to local diets 
and economies in many countries [6, 7]. Expanding the 
aquaculture sector has the potential to reduce the burden 
on wild fish stocks whilst meeting the dietary needs of 
the population for n-3 LCPUFA and other nutrients [8]. 
However, there is a strong need to understand the effect 
of pressures from sustainability on methods of produc-
tion and the health-giving properties of fish. In the past 
decades, the aquaculture industry has improved the sus-
tainability of fish production by lowering the input–out-
put ratios for salmon [9]. Traditional fish oil in formu-
lated fish diets is increasingly being replaced by oil from 
plant-based sources. Among such oils, rapeseed oil is the 
most frequently utilized fish oil alternative in European 
aquaculture systems, mainly due to its ready availability 
and favorable price [10]. However, use of a terrestrial oil 
such as rapeseed may lower concentrations of the main n-3 
LCPUFA, eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA), as well as other important nutrients 
in fish, and thereby the subsequent health benefits to the 
consumer [11]. Consequently, the objective of this study 
was to: (i) assess the effects of consuming two portions per 
week of farmed salmon reared on different feeding regimes 
on the omega-3 index (primary outcome), micronutrient 
concentrations and cardiovascular health outcomes, (sec-
ondary outcomes) in healthy subjects and (ii) evaluate how 
changes in health outcomes may be related to composi-
tional differences of the salmon.
Subjects and methods
Growing of salmon
Atlantic salmon (Salmo salar L.) were grown by Marine 
Harvest (now MOWI) at Ardnish fish farm in Lochailort, 
United Kingdom, between April 2012 and January 2013 on 
fish feed that was produced to differ in n-3 LCPUFA (Bio-
Mar Ltd). One group of salmon received traditional high 
fish meal and high fish oil feed with high concentrations 
of EPA and DHA (FO group: EPA + DHA ~ 15% of total 
feed fatty acids); whereas, the other group of salmon were 
fed diets where the majority of the fish oil was replaced by 
vegetable oils (mainly rapeseed oil) with lower concentra-
tions of EPA and DHA (RO group: EPA + DHA ~ 6–8% of 
total feed fatty acids). The composition of the fish diets and 
feeding schedule is outlined in Supplementary Tables 1a and 
1b. After 9 months, salmon length and weight were similar 
between both groups (Supplementary Table 2). Fish were 
harvested, gutted and filleted, and two portions were cut 
from the center part of each salmon. The average portion 
size was 157.1 g (SD 43.5 g, n = 300) for FO salmon and 
153.9 g (SD 33.6 g, n = 300) for RO salmon. Fillets were 
vacuum packed, snap frozen and stored at − 80 °C for the 
duration of the human intervention study. Storage of salmon 
at − 80 °C for 12 months did not affect the fatty acid com-
position of the salmon (Supplementary Fig. 1).
Compositional analysis of salmon fillets
Routine proximate analytical procedures were used to estab-
lish the macronutrient composition of the salmon. Total fat 
was determined by the Soxtec method (Soxtec 2050 Auto Fat 
Extraction System) [12]. Protein was measured as total nitro-
gen by the Dumas combustion method using a Vario Max 
CN analyzer. The nitrogen content was multiplied by 6.25 
to calculate the protein concentration [13]. For fatty acid 
analysis, total lipids from diet subsamples were extracted 
using the method of Folch [14], and total lipid was then 
converted to its methyl esters by direct trans-esterification 
using 1% sulphuric acid in methanol. The proportion of indi-
vidual fatty acids in the diet was determined with an Agilent 
6890 gas chromatograph fitted with a 30 m DB23 capillary 
column (J&W Scientific, Folsom, CA, USA) as described 
by us previously [15]. Trace element concentrations were 
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determined after digestion in nitric acid using the MARS 
6 digestion system (CEM Corp., Matthews, NC, USA) by 
inductively coupled mass spectrometry (ICP-MS) analysis 
as previously described [16]. The accuracy of methods was 
assessed using certified reference materials (skimmed milk 
powder, LGC Group, Middlesex, UK, and whole blood, 
SERO AS, Billingstad, Norway). The composition of the 
salmon fillets is indicated in Table 1.
Human intervention study
Ethics
The study was carried out in accordance with the ethical 
principles of the Declaration of Helsinki and Good Clinical 
Practice. The study was approved by the Ethics Committee 
of the Rowett Institute, University of Aberdeen.
Study subjects and study design
This was a randomized parallel intervention study in healthy 
and free-living male and female subjects. All subjects pro-
vided informed consent and completed a health question-
naire prior to starting the study. Eligibility was established 
through a health questionnaire and a screening blood sample. 
Inclusion criteria were men and women aged 35–75 years; 
BMI ranging from 25–35 kg/m2; normal results on full blood 
count (haematocrit above 40% for males and above 35% for 
females; hemoglobin above 13 g/dL for males and above 
11.5 g/dL for females); blood pressure below 160/90 mmHg; 
fasting plasma glucose < 7 mmol/L; normal results of fasting 
plasma lipids (total cholesterol < 8 mmol/L, total/HDL cho-
lesterol < 6 mmol/L). Exclusion criteria were regularly tak-
ing aspirin or aspirin-containing drugs, or other anti-inflam-
matory drugs; taking drugs or herbal medicines known to 
alter the haemostatic system in general; taking any medicine 
known to affect lipid metabolism; taking dietary supple-
ments/multivitamin tablets; diagnosis of diabetes, hyper-
tension, renal, hepatic, hematological disease or coronary 
heart disease; having given a pint of blood for transfusion 
purposes within the last month; unsuitable veins for blood 
sampling; inability to understand the participant information 
sheet; inability to speak, read and understand the English 
language.
Study protocol
Eligible subjects were randomized to 1 of the 3 possible 
parallel interventions, matched for gender, age and BMI, 
by an independent statistician, based on the employment of 
covariate balancing/minimization. Subjects were then asked 
to either consume (i) 2 portions of FO salmon per week 
on top of habitual fish consumption, (ii) 2 portions of RO 
salmon per week on top of habitual fish consumption, or (iii) 
continue with habitual fish consumption (Control), for 18 
weeks. Either FO or RO salmon portions were provided to 
the subjects in each group at the start of the study and at their 
9-week study visit. The primary outcome in this study was 
the O3I. A daily intake of ~ 0.5 g n-3 LCPUFA was expected 
to increase the O3I from ~ 4% to ~ 6% after 18 weeks, and 
a daily intake of ~ 1 g n-3 LCPUFA would be expected to 
produce twice this increase [17, 18]. Five previous human 
Table 1  Levels of nutrients 
in salmon fillets used for the 
intervention
Values are means ± SEMs (n = 5 fillets)
FO salmon RO salmon p value
(g/100 g wet weight fillet)
Protein 19.4 ± 0.8 19.1 ± 0.5 0.39
 Total N 3.1 ± 0.1 3.1 ± 0.1 0.39
Carbohydrates 0.2 ± 0.0 0.1 ± 0.0 0.02
 Fat, total 10.8 ± 2.1 10.8 ± 1.5 0.98
  Saturated fat 3.0 ± 0.6 2.3 ± 0.3 0.04
  Monounsaturated fat 3.7 ± 0.7 4.7 ± 0.6 0.06
  Polyunsaturated fat 4.1 ± 0.8 3.8 ± 0.5 0.56
   n-6 PUFA 1.5 ± 0.1 2.1 ± 0.1 0.00
   n-3 PUFA 2.6 ± 0.1 1.7 ± 0.1 0.00
    EPA + DHA (% of total fat) 2.1 ± 0.4 (19.5%) 0.9 ± 0.1 (8.8%) 0.00
Moisture 63.4 ± 2.0 65.3 ± 3.1 0.30
Ash 2.2 ± 0.2 2.0 ± 0.2 0.19
Vitamin  D3 (µg/100 g) 1.8 ± 0.1 1.4 ± 0.1 0.00
Selenium (µg/100 g) 17.8 ± 2.2 19.3 ± 4.5 0.30
Zinc (µg/100 g) 578.3 ± 108.9 622.4 ± 23.5 0.16
Magnesium (mg/100 g) 28.6 ± 3.2 26.3 ± 1.9 0.60
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intervention studies with n-3 LCPUFA showed an average 
SD index% between 0.78 and 0.92%, with a mean SD of 
change of 0.85% (data supplied by W. Harris). To detect 
a group difference of 1% for this SD, on the basis of a 5% 
significance level and a power of 90% for detecting a main 
effect on the omega-3 index, a sample size of 17 per each 
intervention and control group would be required.
Subjects attended the Human Nutrition Unit at the Rowett 
Institute in Aberdeen, United Kingdom, after an overnight 
fast of ≥ 10 h, just before the start of the study, and after 9 
and 18 weeks of intervention, where their blood pressure 
and heart rate were measured, and a blood sample was taken. 
Prior to the visits at the start and during the 18th week of 
intervention, 4-day estimated food diaries were recorded 
by each participant. Blood samples (70 mL) were obtained 
using siliconized 21-gauge butterfly needles into vacutain-
ers containing either EDTA as anticoagulant or vacutainer 
serum tubes (Becton Dickinson, Oxford, UK). Whole blood 
samples were used for blood cell count using a Sysmex 
KX21 (Sysmex Ltd, UK). 100 µL of whole blood was fro-
zen at − 70 °C for the analysis of fatty acid composition in 
red blood cells (RBC). Plasma was obtained by centrifug-
ing whole blood at 2000g for 15 min and stored at − 70 °C 
for the analysis of markers of lipid metabolism, glucose, 
insulin, inflammation and elements. Serum samples were 
collected after whole blood was left to clot for 1 h and then 
centrifuged for 2000g for 15 min. The serum was stored at 
− 70 °C for the analysis of 25(OH)D3.
Compliance was calculated at the end of the study from 
participant’s diaries and fish logs with the following for-
mula: compliance (%) = number of salmon portions eaten 
over 18 weeks/36 (number that should have been eaten over 
18 weeks). The 4-day food diaries were analyzed with the 
NetWISP analysis program (version 3.0) (Tinuviel Software, 
Llanfechell, Anglesey, UK) using the UK Nutrient Databank 
[19].
Biochemical analyses
Fatty acid composition in red blood cells
Fatty acid composition in red blood cells (RBC) was per-
formed as described by Harris et al. [18], using an Agilent 
6890 gas chromatograph as described above [15]. The O3I 
was subsequently calculated as the absolute amount of 
EPA + DHA as percentage of total fatty acids [17].
Analysis of cardiovascular risk markers
Glucose, total cholesterol, HDL cholesterol, triacylglycerols 
and non-esterified fatty acids (NEFAs) were measured in 
plasma on an automated clinical analyzer (KONELAB30, 
Thermo Fisher Scientific, UK) using kits obtained from 
Microgenics GmbH, UK. LDL cholesterol was calculated 
with the Friedewald formula [20]. Clottable fibrinogen was 
measured in plasma in duplicate according to the method 
[21] in a semi‐automated coagulometer (Schnitger and 
Gross, Burkard Scientific (Sales) Ltd., UK). Soluble inter-
cellular adhesion molecule‐1 (sICAM‐1), soluble P‐selec-
tin (sP‐selectin) and high-sensitivity C-reactive protein (hs-
CRP) were analyzed in plasma with Platinum ELISA kits 
(Bender MedSystems GmbH, Austria); insulin was analyzed 
in plasma with a Mercodia ELISA kit (Mercodia, Uppsala, 
Sweden). All samples were measured in duplicate.
Vitamin D analysis
The vitamin D metabolite 25(OH)D3 was analyzed in serum 
as described [22]. This LC–MS/MS method has previously 
been validated against other commercially available assays 
and is regarded as the most valid and reliable technique for 
the assessment of vitamin D metabolites including 25(OH)
D3 [23]. All samples were measured once, with a subset of 
9 samples measured in duplicate.
Trace element analysis
Plasma concentrations of selenium, zinc and magnesium 
were analyzed by diluting plasma into concentrated nitric 
acid (65% (v/v) and then incubating at 165 °C for 10 min 
followed by analysis using ICP-MS as previously described 
[16]. The accuracy of the method was assessed using cer-
tified reference materials: whole blood (Seronorm Whole 
Blood L-3) and serum (Seronorm Serum L-1) (SERO AS, 
Billingstad, Norway). The median recovery values of the 
relevant elements were within the certified ranges indicated 
by the supplier. All samples were measured in duplicate.
Statistical analysis
Statistical analysis was carried out using R 3.4.0 (R Founda-
tion for Statistical Computing, Vienna). Baseline data were 
analyzed by Analysis of Variance with terms for participant 
age, gender, BMI and treatment group. Outcome data were 
analyzed by Analysis of Variance with terms for participant 
age, gender, BMI, baseline value and treatment group. The 
treatment term was also split into contrasts between the con-
trol and intervention diet. We also examined analyses includ-
ing interactions between treatment group and participant, 
age and gender, but these were not significant. Models with 
a time of year effect were also examined, and although these 
effects were significant for some outcomes, they did not 
affect the conclusions about treatment effects. Differences 
between treatment groups were tested by post hoc tests with 
Tukey adjustment for multiple comparisons. Results at 9 and 
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18 weeks are presented as separate analysis, as a repeated 
measures analysis did not add any additional information.
Results
Salmon composition
FO salmon contained 10.8 g/100 g fat of which 10.5% 
was EPA and 9% DHA (Table 1). Thus, two 157.1 g por-
tions/week of FO salmon provided ~ 6.6 g of EPA + DHA 
per week (or ~ 0.9  g/day). RO salmon also contained 
10.8 g/100 g fat of which 4.2% was EPA and 4.6% was 
DHA (Table 1). Thus, two 153.9 g portions of RO salmon 
provided ~ 2.8 g of EPA + DHA per week (or ~ 0. 4 g/
day). Consumption of two portions/week of either the 
FO or RO salmon provided ~ 4–5% of the RDA for vita-
min D, ~ 15% of the RDA for selenium, and ~ 3–6% of 
the RDA for zinc and magnesium (Table 1). FO salmon 
contained significantly higher amounts of carbohydrates, 
saturated fat, n-3 LCPUFA, EPA + DHA and vitamin  D3, 
and significantly lower amounts of n-6 PUFA, compared 
with RO salmon (Table 1).
Recruitment of subjects
A total of 75 subjects were recruited between November 
2012 and August 2013. Of these subjects, 11 did not meet 
the inclusion criteria and 11 declined to participate. 53 sub-
jects were allocated to the three intervention groups, but one 
participant withdrew because of fainting during blood sam-
pling, and one participant because of an unrelated medical 
intervention. Therefore, 51 subjects completed the interven-
tion with 17 subjects in each of the three intervention groups 
(Fig. 1). The study ended in January 2014. Baseline charac-
teristics of the subjects did not significantly differ between 
these three groups (Table 2).
Assessed for eligibility (n=75)
Excluded (n=22)
• Not meeting inclusion criteria (n=11)
• Declined to participate (n=11)
Allocated to FO salmon 
group (n=19)
Allocated to RO salmon 
group (n=17)
Allocated to Control group 
(n=17)
Analysed (n=17) Analysed (n=17) Analysed (n=17)
Randomized (n=53)
Discontinued intervention (n=2) 
(Fainted after baseline sample (n=1)
Started medical treatment (n=1))
Fig. 1  Flow chart of participant recruitment
Table 2  Characteristics of 
subjects at baseline
Values are means ± SEMs (all such values)
FO salmon (n = 17) RO salmon (n = 17) Control (n = 17)
Age (years) 55 ± 3 53 ± 3 54 ± 3
Sex (female/male) 10/7 10/7 11/6
BMI (kg/m2) 25.9 ± 1.0 25.5 ± 0.9 26.5 ± 1.0
Systolic blood pressure (mm Hg) 131.2 ± 4.2 129.2 ± 3.5 133.4 ± 3.0
Diastolic blood pressure (mm Hg) 80.7 ± 2.3 79.8 ± 1.7 78.1 ± 2.6
Heart rate (beats/min) 64.3 ± 2.3 64.3 ± 2.0 63.1 ± 3.1
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Effect of intervention on dietary intake, compliance 
to fish intervention and body weight
Compliance for the salmon intervention was 83% for 1 par-
ticipant in the RO salmon group and 100% for the other 
33 subjects. Analysis of the food diaries from the subjects 
from the FO salmon, RO salmon and control groups showed 
that there were no significant changes in habitual fish intake 
across the study period (data not shown). Mean intake of 
energy and macronutrients from the diets at baseline and 
after 18 weeks of intervention was not different between 
groups, apart from salt intake at 18 weeks, which was sig-
nificantly higher in the control group than in the FO and RO 
salmon groups (p < 0.05) (Table 3). Mean body weight did 
not change during the intervention period in the FO salmon, 
RO salmon and control groups (data not shown).
Effect of intervention on fish intake, the O3I and RBC 
fatty acid composition
Mean (± SEM) weekly intake of total fish was 3.3 ± 0.1, 
2.9 ± 0.1 and 1.8 ± 0.2 portions, whereas mean (± SEM) 
weekly intake of oily fish was 2.6 ± 0.0, 2.4 ± 0.1 and 
1.0 ± 0.2, in the FO salmon, RO salmon and control groups, 
respectively, during the last week of the 18-week interven-
tion. After both 9 and 18 weeks of intervention, the O3I was 
significantly higher in subjects consuming 2 portions/week 
of either FO or RO salmon, compared with the control group 
(both p < 0.05). After 18 weeks of intervention, the difference 
in the increase of the O3I between those consuming the FO 
(2.3%) and RO salmon (2.0%) was no longer significant 
(Fig. 2a). The changes in the O3I after 18 weeks of inter-
vention correlated significantly with intake of n-3 LCPUFA 
per kg body weight (Fig. 2b). Incorporation of EPA + DHA 
Table 3  Mean daily intake of 
energy, macronutrients, salt, 
fibre and  alcohola in subjects at 
baseline and after 18 weeks of 
intervention
a All values are means ± SEMs. Only subjects providing both food diaries (week 0 and week 18) were 
included in the analysis (n = 15, 17 and 15 in the FO salmon, RO salmon and Control group, respectively). 
ptreatment = p value for treatment effect between groups
FO salmon (n = 15) RO salmon (n = 17) Control (n = 15) ptreatment
Energy (kcal)
 Baseline 1897 ± 133 1775 ± 114 1898 ± 115 0.29
 18 weeks 1844 ± 154 1822 ± 101 1912 ± 114 0.72
Protein (g)
 Baseline 82.0 ± 5.0 70.4 ± 4.2 79.4 ± 5.7 0.43
 18 weeks 74.9 ± 5.5 71.5 ± 3.2 80.3 ± 4.6 0.18
Carbohydrates (g)
 Baseline 227.8 ± 19.3 212.4 ± 14.4 208.6 ± 16.0 0.57
 18 weeks 210.9 ± 22.6 218.8 ± 13.5 204.9 ± 14.9 0.40
Total fat (g)
 Baseline 76.4 ± 5.7 69.0 ± 5.3 80.1 ± 6.5 0.19
 18 weeks 76.8 ± 6.0 71.4 ± 4.8 83.1 ± 5.5 0.55
Saturated fat (g)
 Baseline 27.4 ± 2.6 26.2 ± 2.4 30.6 ± 3.2 0.29
 18 weeks 27.0 ± 2.5 25.7 ± 1.9 32.0 ± 3.3 0.33
Polyunsaturated fat (g)
 Baseline 12.7 ± 1.0 10.9 ± 1.0 12.0 ± 1.4 0.49
 18 weeks 12.9 ± 1.2 12.7 ± 1.3 13.2 ± 1.2 0.88
Monounsaturated fat (g)
 Baseline 22.4 ± 1.8 20.7 ± 1.6 25.1 ± 2.8 0.22
 18 weeks 21.4 ± 2.1 21.3 ± 1.6 25.2 ± 1.9 0.49
Salt (g)
 Baseline 6.1 ± 0.5 6.5 ± 0.7 6.3 ± 0.6 0.89
 18 weeks 5.8 ± 0.6 5.7 ± 0.4 7.2 ± 0.6 0.03
Fiber (g)
 Baseline 21.8 ± 2.0 18.7 ± 1.2 18.9 ± 1.5 0.27
 18 weeks 22.0 ± 2.4 19.9 ± 1.5 20.9 ± 1.9 0.68
Alcohol (g)
 Baseline 4.6 ± 1.7 11.0 ± 2.9 11.6 ± 3.0 0.08
 18 weeks 9.3 ± 3.9 10.3 ± 2.6 11.5 ± 3.0 0.84
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into RBC occurred mostly at the expense of linoleic acid 
and arachidonic acid, and consumption of FO salmon, com-
pared with RO salmon, led to a preferential incorporation of 
EPA into RBC membranes (Fig. 2c, d). Predicted O3I (%), 
calculated with an algorithm based on studies with fish oil 
supplements [24], using a dose of EPA + DHA of 900 mg/
day for the FO group and 400 mg/day for the RO group (see 
above) showed a good alignment with observed O3I values 
for all three intervention groups (Fig. 3).
Effect of intervention on cardiovascular risk markers
Plasma triacylglycerols were significantly lower in subjects 
consuming RO salmon, compared with the control group, 
after 18 weeks of intervention (p < 0.05) (Table 4). None 
of the other plasma lipids were significantly affected by the 
salmon intervention. Heart rate was significantly lower in 
subjects consuming FO salmon, compared with control, 
but only after 9 weeks of intervention (p < 0.01) (Table 4). 
Blood pressure and metabolic markers were not affected by 
the salmon intervention, although revised QUICKI, a marker 
of insulin sensitivity, was slightly but significantly lower in 
the FO group compared with the control group (p < 0.05) 
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9 wk 18 wk 9 wk 18 wk
Fig. 2  Changes in RBC fatty acid composition upon consumption 
of 2 portions of FO or RO salmon per week or no additional salmon 
(control), after 9 and 18 weeks. Data are means ± SEM. a: Change in 
O3I from baseline at 9 weeks and 18 weeks for FO salmon (black), 
RO salmon (gray), control (white) groups; *p < 0.01 for differences 
from control group; #p < 0.05 for difference between FO and RO 
salmon groups. b: Correlation of changes in O3I with the intake of 
EPA + DHA per kg of body weight across the FO salmon (black), RO 
salmon (gray) and control (white) groups after 18 weeks of interven-
tion. Changes in the abundance of individual fatty acids in RBC upon 
consumption of c: FO (black) or d: RO (gray) salmon for 18 weeks. 
*p < 0.05 for differences from control group; #p < 0.05 for differences 














FO salmon: y = 1.1623x - 1.7395
RO salmon: y = 1.2588x - 1.4251
Control: y = 1.3341x - 2.8623
Fig. 3  Predicted versus actual O3I (%). The predicted 
O3I = baseline O3I  −  the predicted change in O3I, with the lat-
ter being calculated with an algorithm based on studies with 
fish oil supplements (21): 2.60 + 0.921  ×  1  –  0.842  ×  baseline 
O3I + 0.05  ×  (baseline O3I)2 + 0.0027  ×  [dose EPA + DHA in mg/
day]  –  0.000000471  ×  [dose EPA + DHA in mg/day]2. The dose of 
EPA + DHA/day used was 900 mg/day for the FO salmon group and 
400 mg/day for the RO salmon group (see “Results”). Black circles 
represent the FO salmon group, gray circles the RO salmon group, 
and white circles the Control group. The solid line represents the line 
y = x, illustrating the ‘perfect prediction’. The dashed lines represent 
the best fit lines of the predicted compared with observed O3I values 
for the FO salmon group (black), the RO salmon group (dark gray) 
and the control group (light gray)
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Table 4  Cardiovascular risk 
 markersa at baseline and after 9 
and 18 weeks of intervention
FO salmon (n = 17) RO salmon (n = 17) Control (n = 17) ptreatment
Systolic blood pressure (mm Hg)
 Baseline 131.2 ± 4.2 129.2 ± 3.5 133.4 ± 3.0 0.896
 9 weeks 130.3 ± 3.5 125.4 ± 2.8 131.5 ± 3.1 0.296
 18 weeks 129.3 ± 3.5 120.8 ± 3.1 129.5 ± 3.9 0.136
Diastolic blood pressure (mm Hg)
 Baseline 80.7 ± 2.3 79.8 ± 1.7 78.1 ± 2.6 0.427
 9 weeks 80.0 ± 1.9 80.2 ± 1.8 81.4 ± 2.1 0.275
 18 weeks 77.9 ± 2.0 75.4 ± 2.1 77.8 ± 2.4 0.374
Heart rate (beats/min)
 Baseline 64.4 ± 2.3 64.3 ± 2.0 63.2 ± 3.1 0.592
 9 weeks 58.4 ± 2.2a 63.9 ± 2.4b 65.4 ± 3.3b 0.002
 18 weeks 61.9 ± 2.0 64.9 ± 2.8 65.0 ± 3.3 0.571
Total cholesterol (mmol/L)
 Baseline 5.42 ± 0.30 5.49 ± 0.22 5.41 ± 0.28 0.864
 9 weeks 5.66 ± 0.33 5.70 ± 0.22 5.54 ± 0.27 0.889
 18 weeks 5.71 ± 0.28 5.46 ± 0.17 5.60 ± 0.27 0.123
HDL cholesterol (mmol/L)
 Baseline 1.52 ± 0.08 1.74 ± 0.14 1.66 ± 0.11 0.251
 9 weeks 1.68 ± 0.10 1.78 ± 0.13 1.74 ± 0.12 0.193
 18 weeks 1.71 ± 0.11a 1.73 ± 0.15b 1.75 ± 0.11a,b 0.012
LDL cholesterol (mmol/L)
 Baseline 3.53 ± 0.26 3.33 ± 0.20 3.35 ± 0.22 0.781
 9 weeks 3.53 ± 0.31 3.53 ± 0.24 3.43 ± 0.19 0.508
 18 weeks 3.52 ± 0.24 3.29 ± 0.20 3.44 ± 0.21 0.393
Triglycerides (mmol/L)
 Baseline 1.35 ± 0.18 1.26 ± 0.13 1.19 ± 0.12 0.660
 9 weeks 1.19 ± 0.15 1.17 ± 0.11 1.19 ± 0.15 0.533
 18 weeks 1.24 ± 0.21a,b 1.08 ± 0.12a 1.31 ± 0.16b 0.050
Glucose (mmol/L)
 Baseline 5.53 ± 0.12 5.67 ± 0.15 5.57 ± 0.12 0.599
 9 weeks 5.73 ± 0.13 5.71 ± 0.22 5.62 ± 0.11 0.711
 18 weeks 5.62 ± 0.10 5.65 ± 0.18 5.66 ± 0.11 0.804
Insulin (mU/L)
 Baseline 7.71 ± 1.83 6.56 ± 0.95 6.13 ± 0.53 0.579
 9 weeks 6.52 ± 0.68 6.45 ± 0.88 6.10 ± 0.64 0.717
 18 weeks 6.86 ± 0.95 6.56 ± 0.80 6.37 ± 0.72 0.845
NEFA (mmol/L)
 Baseline 0.44 ± 0.04 0.44 ± 0.05 0.53 ± 0.05 0.270
 9 weeks 0.44 ± 0.05 0.45 ± 0.05 0.47 ± 0.06 0.455
 18 weeks 0.54 ± 0.05 0.43 ± 0.03 0.45 ± 0.04 0.055
HOMA-IR
 Baseline 1.95 ± 0.50 1.63 ± 0.21 1.53 ± 0.14 0.593
 9 weeks 1.66 ± 0.17 1.65 ± 0.22 1.53 ± 0.17 0.638
 18 weeks 1.66 ± 0.26 1.63 ± 0.19 1.62 ± 0.19 0.725
revQUICKI
 Baseline 0.427 ± 0.016 0.421 ± 0.009 0.414 ± 0.010 0.684
 9 weeks 0.430 ± 0.014 0.424 ± 0.011 0.437 ± 0.019 0.226
 18 weeks 0.404 ± 0.010a 0.421 ± 0.007a,b 0.424 ± 0.011b 0.041
Fibrinogen (g/L)
 Baseline 2.86 ± 0.07 2.62 ± 0.05 2.60 ± 0.10 0.006
 9 weeks 2.74 ± 0.09 2.72 ± 0.08 2.66 ± 0.11 0.267
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the inflammatory markers, fibrinogen, hs-CRP and s-ICAM 
were significantly higher in the FO and RO groups, compared 
with the control group. However, inspection of relationships 
between baseline inflammatory markers and responses in O3I 
and plasma triacylglycerols did not reveal a consistent rela-
tionship between both (Supplementary Fig. 2 ).
Effect of intervention on serum 25(OH)D3, 
and plasma concentrations of trace elements
Serum 25(OH)D3 was significantly higher in subjects con-
suming RO salmon compared with the control group after 
18 weeks of intervention (p < 0.05) (Table 5). Changes in 
serum 25(OH)D3 were also significantly correlated with 
changes in the O3I across all subjects (r = 0.33, p = 0.02). 
Plasma concentrations of selenium, zinc and magnesium 
were not affected after 18 weeks of intervention (Table 5).
Discussion
In this study, consumption of 2 portions of farmed salmon 
per week, raised on fish oil or rapeseed oil-based feeds, 
increased the O3I to a similar extent after 18  weeks. 
a All values are mean ± SEM. ptreatment = p value for treatment effect between groups. Values with different 
superscript letters indicate that end values differ significantly (Tukey adjusted post hoc comparisons)
Table 4  (continued) FO salmon (n = 17) RO salmon (n = 17) Control (n = 17) ptreatment
 18 weeks 2.73 ± 0.10 2.69 ± 0.08 2.58 ± 0.09 0.063
hs-CRP (mg/L)
 Baseline 1.57 ± 0.69 1.68 ± 0.62 0.89 ± 0.27 0.036
 9 weeks 2.89 ± 1.80 1.31 ± 0.63 1.36 ± 0.53 0.610
 18 weeks 1.63 ± 0.87 1.31 ± 0.44 0.66 ± 0.26 0.596
s-ICAM (ng/mL)
 Baseline 334.5 ± 16.0 311.2 ± 16.5 280.4 ± 7.6 0.024
 9 weeks 325.3 ± 18.2 318.0 ± 14.0 279.5 ± 6.4 0.274
 18 weeks 332.9 ± 20.6 308.3 ± 15.5 275.1 ± 7.9 0.760
p-Selectin (ng/mL)
 Baseline 25.67 ± 2.37 25.77 ± 1.58 20.87 ± 1.17 0.100
 9 weeks 24.53 ± 2.08 25.68 ± 1.57 20.95 ± 1.34 0.588
 18 weeks 26.03 ± 2.21 25.03 ± 1.67 21.15 ± 1.20 0.741
Table 5  Concentration of 
serum 25(OH)D3 and plasma 
 micronutrientsa at baseline 
and after 9 and 18 weeks of 
intervention
a All values are mean ± SEM.  ptreatment = p value for treatment effect between groups. Values with different 
superscript letters indicate that end values differ significantly (Tukey adjusted post hoc comparisons)
FO salmon (n = 17) RO salmon (n = 17) Control (n = 17) ptreatment
Serum 25(OH)D3 (nmol/L)
 Baseline 65.91 ± 7.49 49.96 ± 7.00 48.74 ± 5.27 0.155
 9 weeks 63.13 ± 5.09 66.11 ± 10.24 50.29 ± 4.69 0.190
 18 weeks 78.05 ± 7.21a,b 86.14 ± 10.55a 57.76 ± 4.58b 0.043
Plasma selenium (µg/L)
 Baseline 78.88 ± 2.77 73.10 ± 2.45 77.39 ± 2.91 0.304
 9 weeks 79.37 ± 3.67 76.84 ± 2.00 79.10 ± 3.38 0.713
 18 weeks 81.45 ± 3.07 76.65 ± 2.70 79.15 ± 3.44 0.921
Plasma zinc (µg/L)
 Baseline 990.1 ± 86.8 1170.6 ± 65.8 984.5 ± 52.4 0.058
 9 weeks 965.9 ± 84.9 1191.7 ± 88.1 985.4 ± 81.8 0.567
 18 weeks 1083.7 ± 138.5 1360.8 ± 140.1 1024.6 ± 78.2 0.398
Plasma magnesium (mg/L)
 Baseline 18.76 ± 0.46 18.85 ± 0.37 18.90 ± 0.49 0.983
 9 weeks 18.39 ± 0.51 18.79 ± 0.39 18.28 ± 0.40 0.475
 18 weeks 19.05 ± 0.51 18.79 ± 0.31 18.64 ± 0.39 0.615
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Consumption of salmon raised on fish oil-based feed signifi-
cantly decreased heart rate, but only after 9 weeks, and con-
sumption of salmon raised on rapeseed oil-based feed signif-
icantly increased serum levels of 25(OH)D3 and decreased 
plasma triacylglycerols after 18 weeks of intervention. Thus, 
the nutritional and cardiovascular health benefits of rapeseed 
oil-fed farmed salmon in humans were not less significant 
than those of traditionally farmed salmon, despite containing 
only half the amounts of EPA and DHA.
Two other studies assessed the cardiovascular health ben-
efits of consuming differently fed farmed fish. Consump-
tion of Atlantic salmon grown on a 100% fish oil, but not 
on rapeseed oil, significantly increased serum n-3 PUFA 
concentrations and decreased serum triacylglycerols in 
coronary heart disease patients after 6 weeks [25]. Con-
sumption of farmed trout raised on a marine but not plant-
based feed significantly increased the O3I in healthy men 
after 8 weeks [26]. However, the duration of both studies 
may have been too short to reveal the cardiovascular health 
benefits of consuming fish raised on plant-based feeds. 
Whilst it takes days-to-weeks for maximal fatty acid incor-
poration into transport pools including serum/plasma, this 
can take weeks-to-months for functional pools like RBC 
[27], and this likely affects the time scale on which ben-
eficial changes to cardiovascular health outcomes occur. In 
our study, the effects on the O3I and plasma triacylglycerols 
were more pronounced after 18 compared with 9 weeks of 
intervention, especially in the RO salmon group. After 18 
weeks, the difference in O3I between the FO and RO salmon 
groups was no longer significant, although the RBC pool 
may not be as useful as plasma phosphatidyl choline and 
platelet pools for discriminating between different doses of 
n-3 LCPUFA [27].
The efficacy of farmed salmon or omega-3 supplements 
to increase the O3I appear similar (Fig. 3), indicating that 
changes in the O3I can be explained by intake of EPA and 
DHA, and that the bioavailability of n-3 LCPUFA from fish 
and supplements are comparable. The health implications 
of eating two oily fish per week are potentially significant, 
as previous studies have demonstrated that an O3I of ≥ 8% 
is associated with a lower risk of death from cardiovascular 
disease [28] and death from all causes [29]. Consumption of 
two portions/week of RO salmon also beneficially lowered 
plasma triacylglycerols. Other studies have found similar 
effects on serum/plasma triacylglycerols after shorter inter-
vention periods, indicating that such effects are established 
within a couple of weeks, but mostly with relatively high 
intakes of fish (> 500 g/week). A 4-week intervention with 
750 g/week of fatty fish in healthy subjects decreased serum 
triacylgycerols compared with lean meat [30]. Similarly, a 
4-week lean-seafood intervention, supplied as 60% of total 
dietary protein, decreased fasting and postprandial serum 
triacylglycerols compared with a non-seafood intervention 
as part of a controlled diet in healthy subjects, despite the 
fact that both diets contained similar amounts of n-3 LCP-
UFA. Lowered serum triacylglycerol concentrations were 
associated with decreased fasting triacylglycerols in chy-
lomicrons and VLDL, reduced fasting VLDL particle size 
and a reduced postprandial concentration of medium-sized 
VLDL particles [31]. In our study, we also found that con-
sumption of FO salmon significantly decreased heart rate, 
but only after 9 weeks of intervention. Two meta-analyses 
of RCTs found that consumption of fish oil supplements 
reduced heart rate [32, 33], an effect that appeared to be 
predominantly attributable to DHA [32]. Interestingly, fish 
oil reduced heart rate particularly in those with higher base-
line heart rate and those on longer treatment duration [33]; 
whereas, our findings provide evidence for a temporary 
decrease in heart rate. This may indicate that consumption 
of fish oil supplements rather than fish is more effective in 
modulating heart rate, and therefore risk of cardiovascular 
mortality, in the long term.
Fish, especially oily fish such as salmon, is also a major 
dietary source of vitamin D [34] and in our study, serum 
25(OH)D3 concentrations were significantly correlated 
with the O3I. A recent meta-analysis found that consump-
tion of at least two fish meals over 4 weeks was associated 
with a significant increase in 25(OH)D concentrations of 
~ 4.4 nmol/L, albeit that consumption of fatty fish, longer 
study durations and lower baseline 25(OH)D concentrations 
were associated with larger increases in 25(OH)D concen-
trations [35]. However, increased consumption of (mostly 
farmed) fish did not affect plasma 25(OH)D concentrations 
despite increased vitamin D intake in another study [36]. 
In our study, which was not controlled for time of year and, 
thus, exposure to sunlight, subjects who consumed the RO 
salmon significantly improved their vitamin D status com-
pared with subjects in the control group. However, FO and 
RO salmon provided approximately 0.8 and 0.6 µg/day of 
vitamin  D3, respectively, which is well below the recom-
mended 10 µg/day in the UK, or 10–20 µg/day in the USA. 
Therefore, increasing consumption of farmed salmon alone 
may not be sufficient to optimize vitamin D status [35]. Fur-
thermore, vitamin  D3 levels in aquaculture feeds have fallen 
in the past decades [37], as fish feeds with terrestrial com-
ponents are generally devoid of this vitamin, with levels in 
farmed salmon being 25% lower than in wild salmon [34]. 
Therefore, this study highlights the importance of optimiz-
ing levels of vitamin D and other micronutrients in fish feeds 
to enhance the nutritional value of farmed fish to consumers 
in the future.
A growing number of studies have highlighted the 
contribution of fish consumption to adequate intake of 
micronutrients on a global scale [38, 39], although the 
actual contribution of fish to individual micronutrient status 
is debated. Despite increased total fish consumption 
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in Bangladesh in the past two decades, mostly through 
increased consumption of farmed fish, iron and calcium 
intake from fish have decreased, whilst no significant 
changes in intakes of zinc, vitamin A and vitamin  B12 have 
occurred, possibly reflecting lower overall nutritional quality 
of farmed fish [40]. Indeed, selenium levels in farmed 
salmon raised on increased levels of terrestrial-based diets 
have been shown to decrease by 50% [41]. In our study, we 
found no effect of salmon consumption on plasma concen-
trations of selenium, zinc or magnesium, which is perhaps 
expected considering the relatively low contribution of the 
salmon intervention to the RDA for these micronutrients.
This study had several strengths, including its interdis-
ciplinary farm-to-fork design to link sector-representative 
fish feed formulations to key human health outcomes. 
Another strength is the intervention amount, which is 
in line with dietary guidelines, and the relatively long 
study duration, allowing the assessment of both short 
and longer-term effects. Study limitations include a rela-
tively small study population of healthy Caucasian sub-
jects, which limits the extrapolation of findings to other 
relevant groups such as those at risk for cardiovascular 
disease. Another limitation is that power analysis was only 
performed for the primary outcome (omega-3 index) and 
that significant changes in serum 25(OH)D3 and plasma 
triacylglycerol concentrations, and heart rate, could have 
been due to chance. However, these changes are in line 
with those expected based on findings in previous studies.
In conclusion, this study provides robust evidence for 
the cardiovascular health benefits of consuming farmed 
salmon. Moreover, our findings show that introduction of 
more sustainable feeding regimes in the aquaculture sec-
tor does not necessarily compromise the health benefits of 
farmed salmon, as long as two portions/week are consumed.
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Supplemental Table 1a. Fish feed composition 
Feed pellet size 3mm 4.5mm 6.5mm 9mm 12mm 
Salmon group FO  RO  FO RO FO RO FO RO FO RO 
 (%) 
Fish meal 40.8 40.8 42.5 42.5 35.7 35.7 21.0 21.0 24.5 24.5 
Soya cake 3.8 3.8 4.5 4.5 4.5 4.5 6.0 6.0 6.0 6.0 
Wheat gluten 2.5 2.5 - - - - 7.0 7.0 8.0 8.0 
Sunflower cake 11.7 11.7 11.5 11.5 13.0 13.0 13.0 13.0 10.4 10.4 
Corn gluten 7.7 7.7 5.3 5.3 8.0 8.0 15.0 15.0 10.0 10.0 
Fava beans 13.0 13.0 14.5 14.5 13.0 13.0 6.5 6.5 6.5 6.5 
SH fish oil 18.9 8.9 20.1 9.1 24.1 11.1 8.5 2.5 8.2 2.1 
Rapeseed oil - 10.0 - 11.0 - 13.0 9.5 15.7 11.0 17.8 
Palm olein - - - - - - 2.6 8.5 4.0 9.8 
Standard fish oil - - - - - - 7.5 1.4 8.5 2.0 
Supplements 2.7 2.7 2.7 2.7 2.7 2.7 4.8 4.8 4.3 4.3 






Supplemental Table 1b. Feeding schedule 
Diet type Dates fed Feeding period 
3 mm 04 May 2012 – 14 Jun 2012 (6 wk) 6 wk 
4.5 mm 15 Jun 2012 – 23 Aug 2012 (10 wk) 10 wk 
6 mm 24 Aug 2012 – 10 Oct 2012 (7 wk) 7 wk 
9 mm 11 Oct 2012 – 15 Oct 2012 (1 wk) 1 wk 
6 mm 16 Oct 2012 – 11 Nov 2012 (3.5 wk) 3.5 wk 
12 mm 12 Nov 2012 – 5 Dec 2012 (3.5 wk) 3.5 wk 
9 mm + 12 mm 6 Dec 2012 – 18 Dec 2012 (2 wk) 2 wk 




Supplemental Table 2. Salmon length and weight during the fish feeding period 
  FO salmon RO salmon p-value 
Baseline (11 May 2012) 
 Weight (g) (n=100) 102.0 ± 2.2 95.1 ± 2.4 0.037 
 Length (cm) (n=25) 21.9 ± 0.3 20.5 ± 1.0 0.182 
Midpoint (27 September 2012) 
 Weight (g) (n=100) 1.2 ± 0.0 1.2 ± 0.0 0.128 
 Length (cm) (n=50) 43.6 ± 0.4 45.2 ± 0.4 0.004 
Final (7 January 2013) 
 Weight (g) (n=25) 2.4 ± 0.1 2.5 ± 0.1 0.457 







Supplemental Figure 1. Effects of storage on the fatty acid composition of the fish-
oil (FO) and rapeseed oil (RO)-fed salmon. Figures indicate saturated fatty acids 
(SAT), monounsaturated fatty acids (MUFA), n-6 polyunsaturated fatty acids (n-6 
PUFA) and n-3 polyunsaturated fatty acids (n-3 PUFA) as percentage of total fatty 




Supplemental Figure 2. Relationship between plasma inflammatory markers at 
baseline and responses in O3I and plasma triacylglycerols  
